This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    15/02/14

    FDA Advisory Committee rejects cangrelor for PCI - The Medicines Company

    The Medicines Company announced that the FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has voted (7-2) to recommend against...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    07/07/13

    The Medicines Company files cangrelor at FDA to treat PCI

    The FDA has accepted the new drug application (NDA) for The Medicines Company intravenous antiplatelet cangrelor as a treatment in...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    18/01/12

    Cangrelor (AstraZeneca/ The Medicines Company) maintains platelet inhibition and anti-clotting levels prior to Cardiac Surgery

    A study shows that cangrelor, from AstraZeneca/The Medicines Company, has the unique properties of achieving very fast blood thinning effects...

    Journals
    Journal
    31/03/21

    Bridging the gap: Current and future insights for improving suboptimal platelet inhibition in STEMI

    Antiplatelet therapy is one of the cornerstones in the acute treatment of patients with ST-elevation myocardial infarction (STEMI) who undergo primary percutaneous coronary intervention (PCI).

    • Source: International Journal of Cardiology
    Journals
    Journal
    31/08/05

    Evaluation and management of bleeding during cardiac surgery.

    Patients undergoing cardiac surgery with and potentially without cardiopulmonary bypass (CPB) are at risk for excessive microvascular bleeding. This bleeding often leads to transfusion of allogeneic blood and blood components as...

    • Source: Current hematology reports
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    14/03/13

    CHAMPION PHOENIX Phase III trial of cangrelor (Medicines Company) success in PCI

    The Medicines Company has reported results of CHAMPION PHOENIX, a 11,145 patient Phase III randomized, double-blind clinical trial comparing the...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    23/06/15

    FDA approves Kengreal (cangrelor)as adjunctive therapy in PCI-The Medicines Company.

    The Medicines Company announced the approval of Kengreal (cangrelor) by the FDA as an adjunctive therapy to percutaneous coronary intervention...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    12/11/11

    Cangrelor (AstraZeneca) maintains platelet inhibition without major bleeding in Acute Coronary Syndrome patients

    New data demonstrates that intravenous use of cangrelor, from AstraZeneca, was effective at maintaining platelet inhibition in patients on thienopyridines...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    07/09/13

    Phase III trials of cangrelor for PCI confirm advantages

    A pooled analysis of three Phase III clinical trials of cangrelor, from The Medicines Company, confirm the results of the...

    Journals
    Journal
    29/08/18

    Levosimendan use in patients with preoperative low ejection fraction undergoing cardiac surgery: A systematic review with meta-analysis and trial sequential analysis

    The primary aim of this review was to examine the clinical outcomes of levosimendan versus placebo in patients with preoperative low LVEF ≤ 50% undergoing cardiac surgery

    • Source: Journal of Clinical Anesthesia
    See more